The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases
Petrunia AM, Enenko IuA · 1996 · Likars'ka sprava 1996
Reported findings and study design
The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.
93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical findings | Improved clinical measures and longer remission reported; no duration supplied | |
| Study population | 93 patients |
No isolated Vilosen arm or numerical clinical comparison is described.
Source for the extracted data ↗ · Checked 2026-11-01
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- No isolated Vilosen arm or numerical clinical comparison is described.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Citation and original source
Original source: Petrunia AM, Enenko IuA. The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases Likars'ka sprava 1996 1996.
Molekul research summary: https://molekul.io/research/thin-9035846. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry